Using Lactobacillus Plantarum to Prevent Clostridium Difficile Infections in Hospitalized Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine if the Lactobacillus plantarum 299v strain can reduce the risk of Clostridium difficile infections (CDI) in patients receiving antibiotics and immunosuppressive treatment in a nephrology and transplantation ward. A total of 300 adult patients will be enrolled and randomly assigned to receive either the probiotic or a placebo for three months. The study will be conducted over a period of 36 months at the Medical University of Silesia in Poland. The primary focus is on patients who are particularly vulnerable to CDI due to their treatment regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* over 18 years old
* organ transplantation or receiving immunosuppressive drugs for any other reasons
* antibiotics therapy

Exclusion Criteria:

* no consent to participate in the study

Where it's running

• Department of Nephrology, Transplantation and Intenal Medicine Medical University of Silesia
  Poland, Silesian Voivodeship, Poland Recruiting

Study contacts

• Study coordinator: Sylwia Dudzicz-Gojowy, PhD, MD
• Email: sdudzicz@sum.edu.pl
• Phone: +48322591432

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Diet and counseling to see how meals affect gut health after CDI

  We’re testing whether different meal plans and health counseling can influence the gut microbiome and reduce chances of CDI coming back in adults who are being treated for CDI.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT07613645

• Lyophilized fecal microbiota transplant for adults with active ulcerative colitis

  This trial will test whether a dried (lyophilized) fecal microbiota transplant helps adults with active ulcerative colitis when added to their current treatment or started alongside a new advanced medication.

  Recruiting Phase 1 University of Alberta · Calgary, Alberta and 1 other locations · NCT07401680

• How antibiotics versus fecal transplants affect recovery from C. difficile infection

  This project will see how antibiotics and fecal microbiota transplant (FMT) affect adults with C. difficile infection by tracking recovery and biological changes over time.

  Recruiting Umeå University · Umeå · NCT07374094

• Preventing recurrent C. difficile infection with the AZD5148 antibody

  This will try a single dose of the antibody AZD5148 versus placebo to see if it prevents repeat C. difficile infections in adults being treated for a current infection.

  Recruiting at 95 sites Phase 2 AstraZeneca · Phoenix, Arizona and 116 other locations · NCT07285213

• Preventing C. difficile recurrence with short-course oral vancomycin during later antibiotics

  This trial tests whether taking short-course oral vancomycin while you need systemic antibiotics can prevent a recurrence of C. difficile in adults recently treated for CDI.

  Recruiting Phase 2/3 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT06979609

• UDCA added to standard therapy to prevent C. diff recurrence

  This study tests whether taking ursodeoxycholic acid alongside standard antibiotics can reduce recurrence of C. difficile colitis in adults at risk.

  Recruiting Early Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT06884748

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.